PeerVoice Oncology & Haematology Video

Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls

Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Krista Noonan, BSc, MD, FRCPC / Elizabeth R. Plimack, MD, MS, FASCO - Redefining the Standards of Care in RCC: Expert Insights to Translate Recent Advances to Clinical Practice

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma

Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations

John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Christine Brezden-Masley, MD, PhD, FRCPC - Breaking Barriers: Expert Guidance on Best Strategies for Biomarker Testing in Gastric and GEJ Cancers

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What's Next for Patients With HER2+ Gastric Cancer

Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes

Christine Brezden-Masley, MD, PhD, FRCPC - Navigating HER2+ Early Breast Cancer Care: A Multidisciplinary Roadmap to Better Survival

Stephanie Snow, MD, FRCPC - Mastering HER2 in GI Malignancies: Immunotherapy and Chemotherapy Backbones for Optimal Patients Outcomes